October 23, 2020

The Niche

Knoepfler lab stem cell blog

Harvard stem cells

3 min read

I’m enjoying attending and speaking at the annual Science Writers 2018 meeting in D.C. where I spoke this morning on a panel about stem cells. The session was specifically on the Wild West of stem cells. You can follow the meeting events on Twitter with the #sciwri18 hashtag. I had three wonderful fellow panelists, Marilynn Marchione of the AP, Terry Devitt of the University of Wisconsin, and Dr. Peter Marks, Head of CBER at the FDA (pictured). Marilynn and Terry ran the session. The session was …Read More

3 min read

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on the news. (Update, see my new interview after the news broke with ViaCyte CEO Paul Laikind) ViaCyte has been a frequent subject of posts on The Niche related to …Read More

2 min read

There has been considerable discussion about the whether the media hyped the recent Harvard Diabetes stem cell paper (see top 10 takeaways of that paper) . I believe that this was greatly hyped. This Harvard publication reported production of insulin-secreting cells from human embryonic stem cells (hESC). Newspapers around the world widely exaggerated the potential impact of this paper. They often used the word “cure”. Perhaps the worst offender was the Telegraph with their headline “Cure for Type 1 diabetes imminent after Harvard stem-cell breakthrough“. I’m not …Read More